| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMC0910063 |
| P698 | PubMed publication ID | 20112449 |
| P2093 | author name string | Michael J Rinaldi | |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 369 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Taxing sugar-sweetened beverages | |
| P478 | volume | 362 |
| Q33822146 | 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations |
| Q39093102 | A phosphatase-independent gain-of-function mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop. |
| Q39429029 | An in vivo patient-derived model of endogenous IDH1-mutant glioma |
| Q40350325 | Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. |
| Q38014534 | BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques |
| Q26777265 | Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors |
| Q38757601 | Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability |
| Q43405916 | Clinical significance of genetic aberrations in secondary acute myeloid leukemia |
| Q33647411 | Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias |
| Q34302770 | Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms |
| Q34661033 | DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies |
| Q54426186 | Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. |
| Q36401831 | Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation |
| Q38639828 | Driver mutations of cancer epigenomes. |
| Q36001930 | Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies |
| Q38101042 | Epigenetic therapy of hematological malignancies: where are we now? |
| Q38019955 | Epigenetics and blood disorders |
| Q57636775 | Evaluation of mutations in the isocitrate dehydrogenase genes in therapy-related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy |
| Q38329285 | Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. |
| Q38066786 | Genetic and epigenetic alterations of myeloproliferative disorders |
| Q38159973 | Genetic basis of MPN: Beyond JAK2-V617F. |
| Q34752547 | Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. |
| Q35835653 | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F |
| Q43089505 | IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. |
| Q34562170 | IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. |
| Q36522731 | IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression |
| Q37444122 | IDH1 and IDH2 mutations in pediatric acute leukemia |
| Q38227739 | IDH1/2 mutation detection in gliomas |
| Q58023817 | IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis |
| Q33401615 | Immunomodulatory agents in myelofibrosis |
| Q38127417 | Inherited predisposition to myeloproliferative neoplasms |
| Q33965102 | Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism |
| Q54393106 | Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. |
| Q34150008 | JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations |
| Q36612537 | JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. |
| Q38044736 | JAK2 inhibitors in the treatment of myeloproliferative neoplasms. |
| Q37810100 | JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms |
| Q37833893 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond |
| Q49472515 | Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status |
| Q39232415 | Management of myelofibrosis: JAK inhibition and beyond |
| Q33795007 | Metabolism and the leukemic stem cell. |
| Q35873466 | Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients |
| Q26822717 | Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date |
| Q35687860 | Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes |
| Q44429606 | Mutations and prognosis in primary myelofibrosis |
| Q50072000 | Mutations in myeloproliferative neoplasms - their significance and clinical use. |
| Q43106526 | Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms |
| Q40298579 | Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium |
| Q37877727 | Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? |
| Q37869152 | New JAK2 inhibitors for myeloproliferative neoplasms |
| Q48226545 | Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. |
| Q36909019 | Normal and malignant megakaryopoiesis |
| Q43242167 | Novel splicing-factor mutations in juvenile myelomonocytic leukemia. |
| Q38586919 | Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations |
| Q40319899 | Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. |
| Q40784811 | Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin |
| Q40727272 | Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients |
| Q28307278 | Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia |
| Q38100790 | Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians |
| Q44179210 | Screening for IDH mutations in chronic myelomonocytic leukemia |
| Q38429716 | Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies |
| Q39083031 | Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. |
| Q38260977 | Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. |
| Q46070224 | TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms |
| Q41859976 | The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells |
| Q24605258 | The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate |
| Q38683077 | The evolution and clinical relevance of prognostic classification systems in myelofibrosis |
| Q37860336 | Therapeutic approaches in myelofibrosis. |
| Q37968531 | Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? |
| Q35774484 | Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells |
| Q44890063 | Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia |
| Q33581974 | WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations |
Search more.